Accumulation of lipid-laden macrophages (foam cells) is characteristic of atherosclerosis development in the arterial walls. Ferritin nanocages have been found to passively accumulate in the atherosclerotic plaque. Ferritin has been actively investigated as a carrier for contrast agents in atherosclerosis diagnosis. We demonstrate the potential of ferritin as a carrier for therapeutic molecules to mediate cholesterol reduction from foam cells. Cyclodextrin molecules are chemically conjugated to the ferritin nanocages surface or encapsulated within the nanocages using metal co-loading methods. The cyclodextrin-conjugated ferritin has nanomolar affinity to cholesterol molecules. Treatment of foam cells with the conjugates shows decreased levels of intracellular accumulated cholesterol. The preferential localization of ferritin to foam cells is due to transferrin receptor-mediated endocytosis process. These findings show that ferritin nanocages as carriers localize cyclodextrin molecules to foam cells which mediate intracellular cholesterol reduction, thus highlighting its potential use as a therapeutic agent.

The development of protein-polymer complexes using protein cages is garnering attention as a strategy to overcome challenges that relate to immunogenicity and protease degradation. We propose the use of thermoresponsive polymers such as poly(N-isopropylacrylamide) (PNIPAM) to form ferritin-polymer complexes through non-covalent interactions. Ferritin is observed to be released from the complexes after 1–2 days incubation at 37 °C.

No abstract

Nanoparticles (NPs), both organic and inorganic, have been identified as tools for diagnostic and therapeutic (theranostic) applications. Macrophages constitute the first line of defense in the human body following the introduction of foreign antigens, including nanoparticles. However, there is a limited understanding of the cellular fate and trafficking of organic NPs in macrophages as well as the molecular responses that are triggered. This knowledge is crucial for the effective translation of these engineered molecules for theranostic applications. In this work, we performed an in-depth study on the intracellular fate and relevant immune responses of a model organic NP, Archaeoglobus fulgidus ferritin, in murine macrophage (RAW264.7) cells. Ferritin, a naturally occurring iron storage protein, has been reported to target tumors and atherosclerotic lesion sites. Herein, we demonstrate a concentration-dependent internalization mechanism and quantify the subcellular localization of ferritin NPs in various organelles. After NP exposure, export of the iron present in the ferritin core occurred over an extended period of time along with upregulation of iron-related gene mRNA expression. A study on the modulation of the intracellular localization of the NPs was conducted by incorporating peptides to mediate endosomal escape and examining their molecular effects using transcriptional analysis. To further investigate the physiological effects, we monitored the upregulation of immune-related markers (i.e., CCR2, IL1β, TNFα, VCAM-1) along with ROS generation in cells treated with ferritin under various conditions. The in-depth analyses of cellular uptake and responses to versatile protein NPs, such as ferritin, provide basic principles to design and engineer other protein NPs with similar properties for future biomedical applications.

This thesis thus includes the successful incorporation of therapeutic agents for cholesterol sequestration from an atherosclerotic marker, foam cells.Coupled with the internalization properties in macrophages and foam cells, this project emphasizes the potential of ferritin protein cages to be used as transport vehicles for cholesterol reduction in atherosclerosis management.